ADALIMUMAB-ATTO
Manufacturer: Optum Health Solutions (Ireland) Limited
Score: 144.0
AMJEVITA (ADALIMUMAB-ATTO) is a tumor necrosis factor blocker used to treat various conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. The drug has a boxed warning for serious infections and malignancy. It is administered via subcutaneous injection, and dosing varies by condition and patient population. Special considerations are needed for use in pregnancy, pediatric, and geriatric populations.
SERIOUS INFECTIONS and MALIGNANCY: Increased risk of serious infections leading to hospitalization or death, including tuberculosis, bacterial sepsis, invasive fungal infections, and infections due to other opportunistic pathogens. Discontinue AMJEVITA if a patient develops a serious infection or sepsis.
Dose adjustments may be necessary in patients with renal or hepatic impairment.
40 mg every other week
20 mg every other week for patients 15 kg to less than 30 kg, 40 mg every other week for patients 30 kg and greater
160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29
80 mg on Day 1, 40 mg on Day 15, and 20 mg every other week starting on Day 29 for patients 17 kg to less than 40 kg, 160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29 for patients 40 kg and greater
160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29
Not established
80 mg initial dose, followed by 40 mg every other week starting one week after initial dose
Not established
160 mg on Day 1, 80 mg on Day 15, and 40 mg every week or 80 mg every other week starting on Day 29
Not established